Shenyang Xingqi Pharmaceutical Co.,Ltd.

300573

CNE100002DV1

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 2025-06-20			5-day change	1st Jan Change
50.31 ^CNY	-0.95%		-2.04%	+0.94%

06-17	Xingqi Pharmaceutical Begins Phase Three Trial for Anesthetic Gel	MT
05-30	Xingqi Pharmaceutical Says No Adverse Effects Seen in Phase 1 Eye Drops Trial	MT

Xingqi Pharmaceutical Enrolls First Subject for Phase 4 Trial of Eye Drops

Published on 2023-08-17 at 06:56, updated on 2023-08-17 at 06:57

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Shenyang Xingqi Pharmaceutical Co.,Ltd.

Xingqi Pharmaceutical Begins Phase Three Trial for Anesthetic Gel	06-17	MT
Xingqi Pharmaceutical Says No Adverse Effects Seen in Phase 1 Eye Drops Trial	05-30	MT
Shenyang Xingqi Pharmaceutical Co.,Ltd. announced that it expects to receive CNY 850 million in funding	05-26	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	04-28	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024	04-20	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024	24-10-28	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd.(XSEC:300573) added to FTSE All-World Index	24-09-22	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024	24-08-28	CI
Xingqi Pharmaceutical Gets Nod to Trial Eye Drops; Shares Up 4%	24-07-25	MT
Xingqi Pharmaceutical Gets Nod to Register Bromfenac Sodium Eye Drops; Shares Down 3%	24-07-24	MT
Space Peptides announced that it has received funding from Humanwell Healthcare Co.,Ltd., Shenyang Xingqi Pharmaceutical Co.,Ltd., Xiamen Furuier Pharmaceutical Co., Ltd., Purple Knight Capital and other investors	24-05-21	CI
Shenyang Xingqi Pharmaceutical's Q1 Profit Jumps 80%	24-04-26	MT
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	24-04-25	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	24-04-18	CI
Xingqi Pharma Gets Nod to Market Atropine Sulfate Eye Drop; Shares Up 3%	24-03-13	MT
Shenyang Xingqi Pharmaceutical Co.,Ltd. Approves Board Elections	24-01-08	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd.(SZSE:300573) added to Shenzhen Stock Exchange Component Index	23-12-12	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd.(SZSE:300573) added to Shenzhen Stock Exchange Component A Share Index	23-12-12	CI
Xingqi Pharmaceutical's Diquafosol Sodium Eye Drops Bags China's Centralized Drug Bid	23-11-08	MT
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-23	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-28	CI
Xingqi Pharmaceutical Enrolls First Subject for Phase 4 Trial of Eye Drops	23-08-17	MT
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-26	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-19	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-26	CI

Chart Shenyang Xingqi Pharmaceutical Co.,Ltd.

Duration

Period

Chart Shenyang Xingqi Pharmaceutical Co.,Ltd.

300573: Dynamic Chart

SHENYANG XINGQI PHARMACEUTICAL CO., LTD. is a China-based company principally engaged in the research, development, manufacture and distribution of ophthalmic drugs. The Companyâs main products are ophthalmic prescription drugs, including corneal repairing drugs, anti-bacteria drugs, artificial tears, anti-inflammation drugs, anti-allergic drugs, as well as anti-hyperemia & fatigue relief drugs and others. The Company mainly distributes its products within domestic market.

Employees

2,426

Sector

Pharmaceuticals

Calendar

08-27 - Q2 2025 Earnings Release (Projected)

More about the company